23andme semaglutide Unlocking the Genetics of GLP-1 Medications 23andMe plans to launch a

Large-scale cardiovascular outcome trials have demonstrated that certain GLP-1 agonists, including liraglutide, semaglutide, and dulaglutide, reduce the risk of major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors

This panel includes most hormones and variables involved in the diagnosis and treatment of fatigue

Its clean and to the point. The labeling process required walking a line between dietary support and weight-loss claims

This model aims to increase accessibility through geographic or digital proximity (Pozoukidou & Plastara, 2025)

macros: 25g protein ~310 kcal Cost: ~$2.00 7

Gym programs that once leaned heavily on cardio and calorie burn are pivoting toward resistance training packages, strength coaching, protein-first nutrition guidance, and body composition tracking